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Abstract
Background: Hepatitis B virus (HBV) and hepatitis D virus (HDV) infections are major public health problems in
sub-Saharan Africa. Whereas it is known that HBV infection is endemic in Nigeria, there is only little data about
HDV prevalence available. Here, we assessed the HDV seroprevalence and determined the HDV and HBV genotypes
distribution among HBsAg positive individuals in Southwestern Nigeria.
Methods: This cross-sectional study involved 188 serum samples from HBsAg positive outpatients recruited at four
tertiary hospitals in Southwestern Nigeria. Anti-HDV antibodies were detected by ELISA while HDV-RNA was detected
by RT-PCR. Sequencing followed by phylogenetic analyses and HBV genotype-specific PCR were used to characterize
HDV and HBV genotypes, respectively.
Results: Out of 188 HBsAg positive serum samples, 17 (9 %) showed detectable HDV-RNA. Anti-HDV antibodies test
was possible from 103 samples and were observed in 4.9 % (5/103) patients. There was no significant difference in HDV
prevalence between four main cities across the country. 64.7 % of HDV-RNA positive samples were from males and
35.3 % from females (P < 0.05). No significant associations were observed with regard to HDV seroprevalence and
available demographic factors. Phylogenetic analyses demonstrated a predominance of HDV genotype 1 and HBV
genotype E among the HDV-RNA/HBsAg positive patients.
Conclusions: In conclusion, our study showed a high prevalence of HDV infection in HBsAg carriers and the
predominance of HDV genotype 1 infection in Nigerian HBV endemic region. The findings contribute to a better
understanding of the relevance of HDV/HBV co-infection and circulating genotypes.
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Background
Hepatitis D virus (HDV) is a defective RNA virus pre-
senting similarities to some plant viroids, which requires
hepatitis B virus (HBV) as a helper virus for its propaga-
tion. Among 240 million chronic HBV carriers reported
worldwide [1], approx. 15 to 20 million individuals are
also infected with HDV [2–4]. In Africa, of the estimated
65 million chronic HBV carriers, about one fourth of
HBsAg-positive individuals show dual-infection with
HDV [4]. Chronic HBV/HDV co-infection can lead more
often to severe liver diseases, like fulminant hepatitis, if
compared to HBV mono-infection [5], whereas HBV/
HDV super-infection is associated with chronic infection
among 90 % of the virus carriers [3].
HDV is a spherical hybrid particle of ~36 nm in diameter,
composed of an outer coat containing hepatitis B surface
antigens (HBsAg) and host lipids. The inner nucleocapsid
consists of small and large hepatitis D delta antigens
(sHDAg and LHDAg) and a single-stranded, circular RNA
molecule of ~1.7 kb [6, 7]. The unique open reading frame
of the HDV genome encodes the delta antigens. sHDAg is
required for HDV genome synthesis while LHDAg inhibits
HDV-RNA synthesis and is essential for HDV particle
* Correspondence: bockc@rki.de
Oluyinka Oladele Opaleye spent 3 months at the RKI to characterize the
molecular epidemiology of the HBV and HDV isolates.
†Equal contributors
5Department of Infectious Diseases, Division of Viral Gastroenteritis and
Hepatitis Pathogens and Enteroviruses, Robert Koch Institute, Seestr. 10,
D-13353 Berlin, Germany
Full list of author information is available at the end of the article
© 2016 Opaleye et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Opaleye et al. Virology Journal  (2016) 13:61 
DOI 10.1186/s12985-016-0514-6
formation [8]. Currently, eight HDV genotypes (HDV1-8)
have been described with variable geographical distribu-
tion [9–11]. HDV1 is the most common genotype that
distributes globally [9]. HDV2 is prevalent in Asia while
HDV3 is detectable in South America. In sub-Saharan
countries, the prevalence of HDV1, HDV5, HDV6, HDV7
and HDV8 has been reported previously [4, 12, 13]. Clin-
ically, HDV1 infection is associated with both severe and
mild liver disease, whereas HDV2 and HDV3 are associ-
ated with mild clinical course and outbreaks of severe
fulminant hepatitis, respectively [14]. However, there is
limited information on the clinical course of the other
five HDV genotypes.
The HDV prevalence has been reported in various parts
of the world. In Africa, the anti-HDV antibody prevalence
in HBsAg carriers was reported only in Cameroon
(17.6 %) and Gabon (15.6 % to 70.6 %) [13, 15, 16]. Re-
cently, HDV prevalence in sub-Saharan Africa was esti-
mated from 1.3 % to 50 % [4]. Although HBV is endemic
in Nigeria, data on HDV seroprevalence are limited. A
previous study showed that HDV antigen was detectable
in 6.5 % of patients with chronic hepatitis B in Southwest
Nigeria [17]. In addition, another study reported an anti-
HDV prevalence of 12.5 % in 96 HBsAg positive patients
[18]. Moreover, a recent study showed that HDV1 prevails
with 53.3 % in Southwestern Nigeria followed by the
HDV5 (33.3 %) and HDV6 (13.3 %), which were more re-
stricted to the northern part of Nigeria [4].
Early childhood transmission is considered to be the
most important route of HBV infection in high endemic
areas therefore HDV super-infections contribute consid-
erably to the high burden of chronic liver disease [12].
Although the HBV vaccination program into the routine
children immunization schedule has been introduced in
2004 [19], HBV infection still remains a major public
health problem in Nigeria with 10–15 % of the popula-
tion positive for HBsAg [20]. Molecular epidemiology
studies of HDV prevalence and determination of circu-
lating HBV and HDV genotypes in HBV endemic re-
gions of Africa are needed to assess and improve the
control measures of HBV/HDV co-infection. In this
study, we therefore investigated the HDV seroprevalence
and circulation of HBV and HDV genotypes in HBsAg
positive serum samples from Southwestern Nigeria.
Methods
Study area and serum sample collection
One hundred and eighty-eight serum samples obtained
from HBsAg positive outpatients were included in this
cross-sectional study conducted between June and
September 2014 in four tertiary hospitals in southwestern
Nigeria. The four tertiary hospitals were Ladoke Akintola
University Teaching Hospital in Osogbo, Ladoke Akintola
University Teaching Hospital Ogbomoso, Obafemi
Awolowo Teaching hospital Ile-Ife, and University
College Teaching Hospital Ibadan. Of the 188 samples,
123 were from Ibadan, 26 from Ogbomoso, 24 from
Osogbo, and 15 from Ife. The outpatients came to the
hospital for various complaints and routine examination.
Therefore, no patient with severe liver disease was re-
cruited. No information about treatment history was avail-
able from these outpatients. Due to small volume of the
samples only 103 samples could be analysed for the pres-
ence of anti-HDV antibodies.
Ethics
Ethical approval was obtained from the Ladoke Akintola
University Teaching hospital ethical committee. Informed
written consent was sought and obtained from each of the
participants in this study.
Serology of HBV and HDV
All samples had been tested and confirmed for HBsAg
positivity using Rapid Kit (Micropoint Rapid Diagnostic,
Micropoint Bioscience, Switzerland). Relative sensitivity
and specificity were >99 % and 97.0 % respectively, with
accuracy of 98.5 %. HBsAg negative serum samples were
excluded from the study. However, anti-HIV and anti-
HCV analyses have not been done in this study. Total
anti-HDV antibodies (IgG and IgM) were detected using
ELISA (ETI-AB-DELTAK-2, Dia-Sorin, Italy). All sero-
logical tests were performed following the manufacturer’s
instructions.
Detection of HDV-RNA
Nucleic acid was extracted from patient sera using High
Pure Viral Nucleic Acid Kit (Roche, Grenzach-Wyhlen,
Germany) following the manufacturer’s instruction and
stored until use in aliquots at -80 °C. We employed
HDV-specific nested RT-PCR approach for HDV detec-
tion using primers designed for amplification of a highly
conserved region of the HDV genome (LHDAg region,
nucleotide 888 to 1122). The first round of RT-PCR was
performed using a one-step RT-PCR kit (QIAgen, Hilden,
Germany) and primer pair of HDV-04 and HDV-05 [21].
The primer pair HDV-06 and HDV-07 was used for
nested PCR. Primer design and localization in the HDV
genome has been previously described [21]. cDNA synthe-
sis and pre-denaturation was performed at 50 °C for
30 min followed by 95 °C for 15 min. PCR amplification
was for 35 cycles including: denaturation at 94 °C for 30 s,
annealing at 56 °C for 30 s, extending at 72 °C for 45 s,
followed by a final extension for 10 min at 72 °C. The
nested PCR was initiated by a denaturation step at 95 °C
for 2 min and 29 cycles at 94 °C for 30 s, 58 °C for 30 s,
and 72 °C for 45 s, followed by a final extension for 5 min
at 72 °C. 5 μl of each PCR product was analysed by 1.5 %
agarose gel electrophoresis. A positive HDV PCR product
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was described by a band size of 235 bp (first PCR 323 bp)
on the agarose gel. In order to avoid cross contamination,
sample processing (DNA/RNA extraction, template
preparation, and master mix preparation) and PCR was
performed in separate laboratory rooms, which are all certi-
fied for molecular diagnostics using standard precautions.
HDV genotyping and phylogenetic analysis
HDV genotyping was performed by using direct sequen-
cing. HDV positive PCR fragments were extracted from
agarose gelelectrophoresis and purified using a gel ex-
traction kit (Qiagen MinElute gel extraction kit, Hilden,
Germany) according to the manufacturer’s instruction.
Sequencing reactions were performed using 1–5 μl
purified PCR products, 1 μl BigDye reaction mix (Life
Technologies, Applied Biosystems, Darmstadt, Germany)
and 0.5 μM of the primers HDV-06 and HDV-07. Se-
quencing results were analyzed using BioEdit 9.7 soft-
ware (http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and
Geneious Pro (Version 5.5.7, Biomatters Ltd, Auckland,
New Zealand, http://www.geneious.com). The phylogenetic
tree reconstruction and the mean value of genetic diversity
of DNA sequences were carried out using MEGA 5
software [22]. The evolutionary history was inferred
using the Neighbor-Joining method. The evolutionary
distances were computed using the Maximum Composite
Likelihood method. For alignment and HDV genotyping,
eight prototype HDV-genotype sequences retrieved from
the NCBI Gene bank were used (HDV-genotype 1: X77627,
M92448, AB118848, AJ000558, X85253, AY633627,
AF098261; HDV-genotype 2: AJ309880, X60193, U19598,
AF104624; HDV-genotype 3: AB037948; HDV genotype 4:
AF209859; HDV-genotype 5: AM183326; HDV genotype 6:
AM183329; HDV-genotype 7: AM183333; HDV genotype
8: AX741169).
HBV genotyping
HBV-DNA was amplified by HBV genotype-specific
nested PCR using generic outer primers (P1 and S1-2),
Table 1 Patient data, detection of HBsAg and anti-HDAg in Nigerian patient samples
Patient Age (years) Gender (f/m) Region/City HBsAg (+/-) anti-HDV λ450_620nm HDV-RNA (+/-) HDV genotype
14-366 45 f Osogbo + n.d. + 1
14-374 n.d. n.d. Ibadan + n.d. + 1
14-375 n.d. n.d. Ibadan + n.d. + 1
14-386 30 m Ibadan + 0.021 -
14-387 34 f Ibadan + n.d. + 1
14-388 38 m Ibadan + n.d. + 1
14-389 n.d. m Ibadan + n.d. + 1
14-392 18 f Ibadan + 0.884 -
14-403 25 m Ibadan + n.d. + 1
14-406 24 f Ibadan + n.d. + 1
14-408 14 m Ibadan + n.d. + 1
14-415 24 m Ibadan + 1.016 -
14-420 14 m Ibadan + 0.803 -
14-425 33 f Ibadan + 0.701 -
14-426 68 f Ibadan + n.d. + 1
14-432 n.d. m Ibadan + 1.044 -
14-444 n.d. f Ibadan + n.d. + 1
14-445 34 m Ife + n.d. + 1
14-448 30 m Ife + n.d. + 1
14-460 46 f Ibadan + 0.277 -
14-472 19 m Ibadan + n.d. + 1
14-495 49 m Ibadan + n.d. + 1
14-496 34 m Ibadan + n.d. + 1
14-509 32 m Ibadan + 1.128 -
14-562 n.d. n.d. Osogbo + n.d. + 1
Patient numbers are indicated as 14-XXX; the region/cities are located in south-western Nigeria within 200 km; OD (λ 450_620 nm); OD of >1.2 is not reactive, OD
of 0.9-1.2 is borderline reactive, OD <0.9 is reactive. n.d. is not defined or data not available
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followed by duplex primer mixtures containing type-
specific inner primers as described elsewhere [23].
Statistical analysis
Statistical analysis was performed using SPSS version 15
(IBM Corporation, Armonk, NY, USA). Categorical data
were compared by Fisher’s exact test. Non-parametric
data were compared by using the Chi-square test, with
a 2-tailed P value <0.05 considered to be statistically
significant.
Results
Sample characteristics and HDV prevalence
Of the 188 HBsAg positive serum samples from outpa-
tients recruited at four tertiary hospitals in Southwestern
Nigeria, 82 (43.6 %) were from females and 106 (56.4 %)
were from males. The mean age of all the HBsAg posi-
tive patients was 32 ± 10.8 years, and there was no sig-
nificant difference between males (32.2 ± 11.4 years) and
females (31.8 ± 10.5 years). Due to the low volume of
serum samples available, only 103 of the 188 HBsAg
positive samples could be examined for prevalence of
anti-HDV antibodies; however, HDV genome detection
was possible from all 188 samples. Of 103 samples, five
(4.9 %) were positive for anti-HDV antibodies (IgM and
IgG). Unexpectedly, none of the anti-HDV antibodies
positive samples were HDV-RNA positive. 17 of the 188
HBsAg-positive serum samples demonstrated detectable
HDV-RNA given a HDV prevalence of 9 % in our study
population (Table 1, Fig. 1).
Determination of gender affinity showed that 11 of the
17 (64.7 %) HDV-RNA positive serum samples were
from males and six (35.3 %) were from females (P = 0.6).
A more detailed analysis of the regional distribution in
Southwestern Nigeria showed that HDV-RNA detection
in HBsAg-positive individuals is more frequent in Ife
(2/15; 13.3 %) than in any of the three remaining cities
including Osogbo (2/24; 8.3 %), Ibadan (12/123; 9.8 %),
and Ogbomoso (1/26; 3.8 %). However, the difference
was not statistically significant (P > 0.05). Analysis of
Fig. 1 Representative agarose gel electrophoreses of amplified HDV-products. a HDV specific nRT-PCRs showing results of the first PCR round
(HDV-specific amplicon of 323 bp) and b nested PCR with an HDV-specific amplicon of 235 bp. Lanes 1-21 correspond to PCR results from serum
samples. HDV-positive samples with correct size in (b) are denoted with the patient number, e.g., 14-445 (see (b) lane 13 and 21; upper lanes, and
lane 4 and 10, lower lanes). PC is the HDV-positive control (acc. No. M21012, [27]); NC is the negative control. Lane M shows a 100 bp DNA ladder,
base pairs (bp) of the marker are denoted at the left
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Fig. 2 (See legend on next page.)
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the age dependency of HDV-RNA detection showed
that patients within the age range of 31–40 years had
highest prevalence of HDV-RNA with 7/17 (41.2 %),
followed by the age group of 21–30 years with 3/17
(17.6 %). The patients with age range of 11–20 years,
41–50 years and ≥51 years had similar prevalence of
HDV-RNA with 2/17 (11.8 %). As expected, the lowest
HDV-RNA prevalence was found within the age group
of 0–10 years with 1/17 (5.9 %).
HDV and HBV genotype distribution in the Nigerian study
population
In order to determine the circulation of HDV genotypes
in Southwestern Nigeria, sequence data for nucleotide
888-1122 of HDV-RNA (LHDAg region) were obtained
for 14 of the 17 HDV RNA-positive samples. The ob-
tained HDV sequences were aligned using BioEdit, Gen-
eious v. 8.1, and phylogenetic analysis was performed
with prototype HDV sequences obtained from the NCBI
GenBank database. The phylogenetic analysis of the 14
HDV isolates showed that all isolates clustered within
the HDV genotype 1 clade (Fig. 2). HDV sequences are
available at the NCBI GenBank database (Acc. No.
KU844264 to KU844277). Additionally, in order to de-
termine the HBV genotype in the HDV-RNA positive
serum samples, HBV genotype-specific multiplex PCR was
performed and the result showed that HBV genotype E
prevails in all 17 HDV-RNA positive serum samples.
Discussion
Although HBV vaccination under the children
immunization schedule has been available in Nigeria
since 2004, HBV infection still remains a serious pub-
lic health issue in this country with a prevalence of
10–15 % in the population [20, 24]. Among the factors
that shape the clinical course of HBV, co-infection with
other viruses such as HCV, HIV and HDV is one major
risk factor. In this study, we showed a high HDV infection
prevalence of 9 % in the Nigerian study population posi-
tive with HBsAg and the HDV1 was frequently circulating
in Southwestern Nigeria.
Co-infection of hepatitis viruses is common because
these viruses share the same route of transmission. HDV
infection requires the presence of the HBV surface
proteins (HBsAg) to assemble the infectious virus [6].
Therefore, HDV infection occurs regularly where HBV
infection is endemic. Data concerning the prevalence of
HDV infection in Nigeria as well as in other sub-Saharan
African countries are limited. Nevertheless, a recent study
showed that among HBsAg positive serum samples in
endemic regions, approximately 10 % were positive for
anti-HDV antibodies and/or HDV-RNA ranging from <2 %
detected in pregnant women in Burkina Faso to approx.
50 % of liver disease patients in Central African Republic
[4]. Our study on HBsAg positive individuals from four
cities in Southwestern Nigeria showed that 9 % were
HDV-RNA positive and therefore representing active
HDV infection. Only 4.9 % of patients were anti-HDV
antibody positive, which is significantly lower compared
to another recent study showing 12.5 % anti-HDV anti-
body positivity [18]. However, asymptomatic infected
patients of this study showed an anti-HDV prevalence
of 4.3 % [18]. This value is in good agreement to our
finding of 4.9 % analysing only asymptomatic individ-
uals. In addition, another previous study reported a
HDV antigen prevalence of 6.5 % in Nigerian HBsAg
positive patients [17].
A limitation of our study is that we had not enough
sample volume from each HBsAg-positive patient at dis-
posal. Therefore, we could test only 103 of 188 serum
samples for anti-HDAg antibodies. However, none of the
anti-HDAg positive samples was HDV-RNA-positive and
on the other hand none of the HDV-RNA positive sam-
ples tested positive for anti-HDAg (Table 1). Accordingly,
we can only speculate about acute or chronic HDV infec-
tion of the patients. However, it can be hypothesized that
the anti-HDAg positive patients without HDV-RNA de-
tection were likely having chronic infection.
The results of our study revealed a high prevalence of
HDV infection, which may contribute to significant mor-
bidity and mortality in HBV-related liver diseases in
Nigeria. In addition, although not statistically significant,
analysis of gender affinity to HDV infection in our study
indicated that male gender is predominantly affected with
HDV (64.7 %) whereas female showed only 35.3 % of the
total HDV positive cohort. This is not unexpected and in
concordance with a recent report showing that more than
75 % of HDV infected patients were males [21].
(See figure on previous page.)
Fig. 2 a Representative HDV sequences of the HBsAg-positive patients aligned with the Nigerian HDV reference sequence JX888098. HDV sequences
spanning the region from nt 887 to nt 1127 showing patient-specific HDV isolates. Notably, HDV reference sequences of pSVL-D3 (Acc. No. M21012;
positive control of the nRT-PCR) has been included to show that there is no cross-contamination. b Phylogenetic analysis inferred from distance
analysis (Kimura 2 parameters model) using neighbor-joining bootstrap 1000 replicate reconstruction from HDV-sequences (nt 888 to nt 1122)
of the Nigerian HDV isolates (highlighted in boldface and designated as NGA and numbers, e.g NGA 14-375) and the corresponding region of
reference sequences showing that the Nigerian HDV isolates clustered in the HDV genotype 1 branch. The Nigerian HDV sequences were compared
to HDV reference sequences gathering the 8 HDV genotypes (HDV1 to HDV8) which are denoted at the right in brackets (accession number, genotype,
and geographic area are denoted in the figure). The numbers at the nodes indicate bootstrapping values. The bar represents nucleotide substitutions
per position. HDV sequences of the patient isolates are available at NCBI Genebank database (Acc. No. KU844264 to KU844277)
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At least eight HDV genotypes have been identified and
HDV1 is the most common and is distributed through-
out the world [25]. The predominance of HDV1 has
been also described for sub-Sahara Africa [11, 25]. In
this regard, our result showed that HDV1 was predom-
inant in Southwestern Nigeria and no African-specific
HDV5 to HDV8 were identified. However, HDV5 and
HDV6 prevalence has been reported in the northern
part of Nigeria [4]. Therefore, the samples from other
parts in Nigeria are needed to characterize the predom-
inance of circulating HDV genotypes in this country.
Furthermore, HBV genotype E is the predominant HBV
genotype detectable in Nigeria [26]. In agreement with
this report, HBV genotype analyses of the HDV positive
samples of our study cohort revealed that HBV genotype
E predominates in Southwestern Nigeria. A close co-
evolution of HDV1 and HBV genotype E seems unlikely,
since HDV1 prevails worldwide whereas HBV genotype
E is largely confined to Africa and is thought to have a
short evolutionary history [4].
Conclusions
In conclusion, our study provides important information
in the HDV infection prevalence and molecular epidemi-
ology of HBV and HDV genotypes circulating in endemic
regions such as Southern Nigeria, which significantly con-
tributes to improve the control measures of these hepatitis
viruses. Future surveillance studies of HBV and HDV in-
fections are therefore of public health importance not only
for Nigeria but also for endemic regions in sub-Sahara
Africa.
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